Non-Small Cell Lung Cancer | Oncology Today with Dr Neil Love: Management of RET Fusion-Positive Non-Small Cell Lung Cancer
Research To Practice | Oncology Videos · Dr. Neil Love
October 25, 202245m 36s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Dr Justin Gainor, including the following topics:
- Ongoing Phase III trials of selective RET inhibitors for non-small cell lung cancer (NSCLC): Potential effects on survival (0:00)
- Significance of non-fusion RET abnormalities in NSCLC (3:33)
- Clinical impact of tumor-agnostic targeted therapy (5:11)
- Incidence and management of chylothorax in patients undergoing treatment with RET inhibitors (8:46)
- Therapeutic approach for patients with RET-rearranged NSCLC and brain metastases (15:24)
- Appropriate use of checkpoint inhibitors for patients with RET-rearranged NSCLC and disease progression on a RET inhibitor (16:45)
- Adjuvant therapy for RET-rearranged NSCLC (26:23)
- Case: A woman in her mid 60s with no smoking history with NSCLC with a RET fusion and disease progression after a response to carboplatin and pemetrexed (31:07)
- Case: A woman in her early 50s with no smoking history with NSCLC with a RET fusion and liver lesions who previously received cisplatin/pemetrexed and pembrolizumab (36:40)
- Case: A woman in her late 60s with NSCLC with a RET fusion and liver and brain metastases (43:28)